Skip to main content

Table 7 Lys751Gln/Asp312Asn genotypes in the study and control groups

From: Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin

Lys751Gln Asp312Asn Melanoma Newborns OR (95% CI), p Breast cancer OR (95% CI), p
   (n = 423) (n = 1017)   (n = 1713)  
AA GG 115 267 1.0 (n.s.) 494 1.1 (n.s.)
   (27.2%) (26.3%)   (28.8%)  
AA AG 28 104 0.6 (n.s.) 153 0.9 (n.s.)
   (6.6%) (10.2%)   (8.9%)  
AA AA 2 16 0.3 (n.s.) 17 0.6 (n.s.)
   (0.5%) (1.6%)   (1%)  
AC GG 46 107 1.0 (n.s.) 151 0.8 (n.s.)
   (10.9%) (10.5%)   (8.8%)  
AC AG 131 334 1.0 (n.s.) 559 1.0 (n.s.)
   (31%) (32.8%)   (32.6%)  
AC AA 28 49 1.4 (n.s.) 77 1.0 (n.s.)
   (6.6%) (4.8%)   (4.5%)  
CC GG 7 20 0.8 (n.s.) 22 0.7 (n.s.)
   (1.6%) (2%)   (1.3%)  
CC AG 27 51 1.3 (n.s.) 67 0.8 (n.s.)
   (6.4%) (5%)   (3.9%)  
CC AA 39 69 1.4 (n.s.) 173 1.5 (1.2–2.1)
   (9.2%) (6.8%)   (10.1%) 0.004 (0.016)1
  1. 1p value calculated with the χ2 test (Bonferroni adjusted value in parantheses)